CO6382139A2 - Anticuerpo anti-cmet novedoso - Google Patents

Anticuerpo anti-cmet novedoso

Info

Publication number
CO6382139A2
CO6382139A2 CO11073992A CO11073992A CO6382139A2 CO 6382139 A2 CO6382139 A2 CO 6382139A2 CO 11073992 A CO11073992 A CO 11073992A CO 11073992 A CO11073992 A CO 11073992A CO 6382139 A2 CO6382139 A2 CO 6382139A2
Authority
CO
Colombia
Prior art keywords
antibody
new anti
cmet antibody
receptor
met
Prior art date
Application number
CO11073992A
Other languages
English (en)
Inventor
Liliane Goetsch
Thierry Wurch
Cedric Bes
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6382139(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/en
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of CO6382139A2 publication Critical patent/CO6382139A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a un anticuerpo novedoso capaz de unirse específicamente al receptor c-Met humano y/o capaz de inhibir específicamente la actividad de tirosina quinasa de dicho receptor, con una actividad antagonista mejorada, comprendiendo dicho anticuerpo una región bisagra modificada.La invención se refiere además a una composición que comprende ese tipo de anticuerpo antagonista de c-Met y su uso coma un medicamento para tratar el cáncer.
CO11073992A 2008-12-02 2011-06-14 Anticuerpo anti-cmet novedoso CO6382139A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2008/055663 WO2010064089A1 (en) 2008-12-02 2008-12-02 Novel anti-cmet antibody
US18450209P 2009-06-05 2009-06-05

Publications (1)

Publication Number Publication Date
CO6382139A2 true CO6382139A2 (es) 2012-02-15

Family

ID=41693124

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11073992A CO6382139A2 (es) 2008-12-02 2011-06-14 Anticuerpo anti-cmet novedoso

Country Status (39)

Country Link
US (4) US8741290B2 (es)
EP (4) EP3757132A1 (es)
JP (3) JP5863458B2 (es)
KR (1) KR101838299B1 (es)
CN (2) CN102227446B (es)
AR (1) AR074439A1 (es)
AU (3) AU2009328318C1 (es)
BR (2) BRPI0923231B8 (es)
CA (1) CA2743433C (es)
CL (2) CL2011001296A1 (es)
CO (1) CO6382139A2 (es)
CR (1) CR20110324A (es)
CY (2) CY1119172T1 (es)
DK (2) DK2370468T3 (es)
EC (1) ECSP11011127A (es)
ES (3) ES2629855T3 (es)
GE (2) GEP20146207B (es)
HK (2) HK1162536A1 (es)
HR (2) HRP20171011T8 (es)
HU (3) HUE035047T2 (es)
IL (2) IL213273A0 (es)
LT (2) LT2370468T (es)
MA (1) MA32892B1 (es)
MX (2) MX2011005677A (es)
MY (2) MY185200A (es)
NZ (1) NZ593853A (es)
PE (1) PE20120343A1 (es)
PH (1) PH12015501515A1 (es)
PL (3) PL3431502T3 (es)
PT (3) PT3135691T (es)
RS (2) RS58018B1 (es)
RU (2) RU2560257C2 (es)
SA (2) SA109300720B1 (es)
SG (2) SG171851A1 (es)
SI (3) SI3135691T1 (es)
TN (1) TN2011000216A1 (es)
TW (2) TWI523866B (es)
WO (1) WO2010069765A1 (es)
ZA (1) ZA201105164B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
EA201201273A1 (ru) 2010-03-10 2013-02-28 Генмаб А/С Моноклональные антитела к с-мет
SG188324A1 (en) 2010-09-03 2013-04-30 Academia Sinica Anti-c-met antibody and methods of use thereof
BR112013010687A2 (pt) 2010-11-03 2016-08-02 Argen X Bv combinações de anticorpos c-met
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
KR101865223B1 (ko) 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
WO2013064700A2 (en) 2011-11-03 2013-05-10 Argen-X B.V. Chimeric polypeptides and methods of use
KR101463098B1 (ko) * 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
CN105050618B (zh) 2012-06-21 2018-11-16 索伦托治疗有限公司 与c-Met结合的抗原结合蛋白
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
ES2530968T3 (es) 2012-10-12 2015-03-09 Spirogen Sarl Pirrolobenzodiazepinas y conjugados de las mismas
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
SG11201508875TA (en) 2013-04-30 2015-11-27 Agency Science Tech & Res Mab 2 anti-met antibody
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
ES2729797T3 (es) * 2013-12-20 2019-11-06 Dev Ct Biotechnology Anticuerpos específicos de la alfa-enolasa y métodos de uso en terapias contra el cáncer
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR20170136536A (ko) * 2015-03-16 2017-12-11 셀덱스 쎄라퓨틱스, 인크. 항-met 항체 및 그 사용 방법
EP3411067B1 (en) * 2016-02-05 2021-10-20 Helixmith Co., Ltd Anti-c-met antibodies and uses thereof
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
MX2018014175A (es) 2016-05-17 2020-02-07 Abbvie Biotherapeutics Inc Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
US20200023072A1 (en) 2016-10-11 2020-01-23 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
RU2741228C2 (ru) * 2016-11-14 2021-01-22 Общество С Ограниченной Ответственностью "Панацела Лабс" Противоопухолевые эффекты вирусного вектора, кодирующего толл-подобный рецептор и агонист толл-подобного рецептора
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018129029A1 (en) * 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
MX2020012418A (es) 2018-05-23 2021-04-28 Adc Therapeutics Sa Adyuvante molecular.
SG11202101298XA (en) * 2018-08-08 2021-03-30 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
CA3146933A1 (en) 2019-09-16 2021-03-25 Marcus KELLY Radiolabeled met binding proteins for immuno-pet imaging
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
JP2024515266A (ja) * 2021-04-08 2024-04-08 ビョンディス・ビー．ブイ． 抗ｃ－ＭＥＴ抗体及び抗体薬物複合体
TW202304929A (zh) * 2021-04-29 2023-02-01 美商艾伯維有限公司 抗c-Met抗體藥物結合物
WO2023173109A1 (en) 2022-03-11 2023-09-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin and osimertinib

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
CZ20031927A3 (cs) * 2001-01-09 2003-10-15 Merck Patent Gmbh Farmaceutický prostředek na bázi inhibitorů receptoru tyrosinkinázy a inhibitorů angiogeneze
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
RU2006124743A (ru) * 2003-12-11 2008-01-20 Дженентек, Инк. (Us) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ДИМЕРИЗАЦИИ И АКТИВАЦИИ с-Мет
DE602005020799D1 (de) * 2004-08-05 2010-06-02 Genentech Inc Humanisierte anti-cmet-antagonisten
EP1874816A4 (en) * 2005-04-26 2010-08-25 Medimmune Inc MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING
CN101321783B (zh) * 2005-07-18 2015-08-26 安姆根有限公司 人抗-b7rp1中和抗体
US8652469B2 (en) * 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
TW200815470A (en) 2006-03-30 2008-04-01 Novartis Ag Compositions and methods of use for antibodies of c-Met
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Also Published As

Publication number Publication date
JP2016117721A (ja) 2016-06-30
SA112331005B1 (ar) 2015-09-13
MY185200A (en) 2021-04-30
DK2370468T3 (en) 2017-06-19
ES2629855T3 (es) 2017-08-16
EP3757132A1 (en) 2020-12-30
RU2011124751A (ru) 2013-01-10
SI3135691T1 (sl) 2018-12-31
AU2016200725C1 (en) 2017-10-19
JP2012510280A (ja) 2012-05-10
US8747850B2 (en) 2014-06-10
GEP20135930B (en) 2013-10-10
BR122019023930B1 (pt) 2021-05-04
AU2017203929A1 (en) 2017-07-06
RS58018B1 (sr) 2019-02-28
CL2011001296A1 (es) 2011-08-26
ZA201105164B (en) 2012-03-28
ES2697098T3 (es) 2019-01-22
TW201023892A (en) 2010-07-01
IL231525B (en) 2019-07-31
SG171851A1 (en) 2011-07-28
AR074439A1 (es) 2011-01-19
MA32892B1 (fr) 2011-12-01
AU2016200725B2 (en) 2017-05-25
KR101838299B1 (ko) 2018-03-14
EP3431502B1 (en) 2020-07-22
RU2015127471A (ru) 2018-12-21
EP3135691B1 (en) 2018-08-15
HUE040553T2 (hu) 2019-03-28
HRP20181868T1 (hr) 2019-01-11
RU2560257C2 (ru) 2015-08-20
JP6309657B2 (ja) 2018-04-11
NZ593853A (en) 2013-03-28
CN103351438B (zh) 2016-04-20
JP6074018B2 (ja) 2017-02-01
MY192567A (en) 2022-08-29
BRPI0923231B8 (pt) 2021-05-25
MX2011005677A (es) 2011-06-30
PT2370468T (pt) 2017-07-13
US20130109841A1 (en) 2013-05-02
ES2827277T3 (es) 2021-05-20
ECSP11011127A (es) 2011-07-29
HK1190414A1 (zh) 2014-07-04
AU2009328318C1 (en) 2017-11-02
IL231525A0 (en) 2014-04-30
EP2370468B1 (en) 2017-04-05
US8729249B2 (en) 2014-05-20
DK3135691T3 (en) 2018-11-19
MX341014B (es) 2016-08-03
SG187518A1 (en) 2013-02-28
AU2017203929B2 (en) 2019-03-28
HRP20171011T1 (hr) 2017-09-22
LT2370468T (lt) 2017-07-10
HUE051288T2 (hu) 2021-03-01
CY1121025T1 (el) 2019-12-11
TW201446805A (zh) 2014-12-16
PE20120343A1 (es) 2012-04-16
US8741290B2 (en) 2014-06-03
AU2009328318A1 (en) 2011-07-28
CN102227446B (zh) 2015-10-21
JP5863458B2 (ja) 2016-02-16
PT3135691T (pt) 2018-11-27
EP2370468A1 (en) 2011-10-05
AU2016200725A1 (en) 2016-02-25
CA2743433C (en) 2019-06-11
SI2370468T1 (sl) 2017-08-31
US20130109844A1 (en) 2013-05-02
PL3135691T3 (pl) 2019-02-28
EP3431502A1 (en) 2019-01-23
BRPI0923231A2 (pt) 2016-01-26
LT3135691T (lt) 2018-11-12
PL3431502T3 (pl) 2020-12-28
US8765128B2 (en) 2014-07-01
PH12015501515A1 (en) 2015-12-14
BRPI0923231B1 (pt) 2020-04-28
US20110239316A1 (en) 2011-09-29
CY1119172T1 (el) 2018-02-14
PL2370468T3 (pl) 2017-09-29
HRP20171011T8 (hr) 2019-01-25
IL213273A0 (en) 2011-07-31
HK1162536A1 (zh) 2012-08-31
AU2009328318B2 (en) 2015-11-05
US20130109840A1 (en) 2013-05-02
WO2010069765A1 (en) 2010-06-24
SI3431502T1 (sl) 2021-01-29
CL2014000181A1 (es) 2014-07-25
CA2743433A1 (en) 2010-06-24
CN102227446A (zh) 2011-10-26
HUE035047T2 (en) 2018-05-02
TN2011000216A1 (en) 2012-12-17
TWI523866B (zh) 2016-03-01
GEP20146207B (en) 2014-12-10
RS56204B1 (sr) 2017-11-30
JP2017099392A (ja) 2017-06-08
KR20110097839A (ko) 2011-08-31
SA109300720B1 (ar) 2013-05-25
CN103351438A (zh) 2013-10-16
PT3431502T (pt) 2020-10-29
CR20110324A (es) 2011-07-28
TWI459964B (zh) 2014-11-11
EP3135691A1 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
CO6382139A2 (es) Anticuerpo anti-cmet novedoso
CL2012003643A1 (es) Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.
BR112015003109A2 (pt) Composto, composição, uso de um composto, e, métodos para tratar ou prevenir um distúrbio, condição ou doença e para tratar diabetes mellitus tipo 2.
CL2014003465A1 (es) Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
ATE469895T1 (de) Cgrp-rezeptorantagonisten
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
CL2011000976A1 (es) Compuestos derivados de isonicotinamida y carboxamida, antagonistas de los receptores de orexina; composicion farmaceutica que los comprende; y su uso para la prevencion de un trastorno del sueno.
EA201100425A1 (ru) Производные пиколинамида в качестве ингибиторов киназы
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2012003503A1 (es) Compuestos derivados de morfolin pirimidinas sustituidos, inhibidores de la proteina quinasa atr; composicion farmaceutica, utiles para la prevencion o el tratamiento de tumores cancerigenos.
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
ECSP099225A (es) Compuestos antagonistas del receptor de glucagón, composiciones que contienen dichos compuestos y procedimientos de uso
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
CL2008000020A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos.
CL2009001274A1 (es) Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer.
CL2008002521A1 (es) Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2010000667A1 (es) Compuestos derivados de ciclohexil-piperazinil-metanona, antagonistas y/o agonistas inverso h3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de la obesidad, diabetes tipo ii y dislipidemia (sol. div. 60-07).

Legal Events

Date Code Title Description
FC Application refused
FG Application granted